Condition (MeSH)
Pneumocystis Infections
ClinicalTrials.gov lists 109 trials for Pneumocystis Infections or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 36.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
10 of the 109 trials are tagged with Pneumocystis Infections itself; the rest are tagged with a narrower condition beneath it.
When did Pneumocystis Infections trials start? (23)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 6 |
| 2024 | 3 |
| 2023 | 6 |
| 2021 | 2 |
| 2020 | 6 |
| 2019 | 3 |
| 2018 | 2 |
| 2017 | 4 |
| 2016 | 2 |
Showing 10 of 23 earlier years.
No forecast is made for this condition: it averages 3.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Pneumocystis Infections trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 8 |
| Phase 1/2 | 1 |
| Phase 2 | 5 |
| Phase 2/3 | 2 |
| Phase 3 | 24 |
| Phase 4 | 9 |
| Not applicable | 29 |
| Observational | 31 |
How many Pneumocystis Infections trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 6 |
| Recruiting | 7 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
| Completed | 75 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Pneumocystis Infections trials? (9)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 36 |
| Fisons | 5 |
| U.S. Bioscience | 5 |
| Glaxo Wellcome | 4 |
| Jacobus Pharmaceutical | 2 |
Showing 5 of 9 sponsors.
Which drugs are being tested for Pneumocystis Infections? (10)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Pentamidine Isethionate | 20 |
| Calcium Leucovorin | 13 |
| Trimetrexate glucuronate | 12 |
| Dapsone | 9 |
| Atovaquone | 9 |
Showing 5 of 10 drugs.
Interventions as named in the registry (5)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Trimethoprim / Sulfamethoxazole | 13 |
| Sulfamethoxazole trimethoprim | 7 |
| MK0991, caspofungin acetate | 3 |
| Clindamycin Gel | 2 |
| Sitamaquine | 2 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Pneumocystis Infections trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Hepatotoxicity | 23 | 1 |
| Death | 17 | 1 |
| Gastroenteritis | 16 | 1 |
| Neutrophil count decreased | 15 | 1 |
| Pneumonia | 11 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Pneumocystis Infections? (11)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| The clinical impact of pneumocystis and viral PCR testing on bronchoalveolar lavage in immunosuppressed patients. | Respiratory medicine | 2018 | Yes |
| Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis. | Antimicrobial agents and chemotherapy | 2004 | Yes |
| Relationship between event rates and treatment effects in clinical site differences within multicenter trials: an example from primary Pneumocystis carinii prophylaxis. | Controlled clinical trials | 1999 | Yes |
| Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. | Antimicrobial agents and chemotherapy | 1998 | Yes |
| Iron chelators as therapeutic agents against Pneumocystis carinii. | Antimicrobial agents and chemotherapy | 1994 | Yes |
Showing 5 of 11 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.